Posted by Michael Wonder on 08 Sep 2020
RadioMedix and Curium announce FDA approval of Detectnet (copper Cu 64 dotatate injection) in the U.S.
7 September 2020 - RadioMedix and its commercial partner Curium announced today that Detectnet (copper Cu 64 dotatate injection) was approved by the U.S. FDA.
Detectnet is a positron emission tomography agent indicated for the localisation of somatostatin receptor positive neuroendocrine tumours in adult patients.
Curium expects to launch Detectnet immediately with doses available through various nuclear pharmacies or directly from Curium.
